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Dear Sir, It has been announced that the National Institutes of Health, Bethesda, USA, is beginning a diabetes control trial aimed at assessing the relationship between blood glucose and microvascular complications in Type 1 (insulin-dependent) diabetes. Twenty-one medical centres in the USA and Canada have been selected [1] .
Recent articles in both the lay [1] and the medical [21 literature have emphasized the idea that the open-loop delivery system will resolve the controversy over diabetic control and the development of complications.
The utility of any clinical trial can be discussed in two ways: is it going to yield more fundamental knowledge (explanatory approach) or will it help to reach a decision on the choice of the best available treatment (pragmatic approach) [317 Thus any trial designed to demonstrate the causal relationship between blood glucose levels and microvascular lesions must be an explanatory one [3] . However, such a trial is not easy to design since two goals more or less overlap: (1) what is the effect of elevated blood glucose levels on the microvasculature and (2) is there any definite pathological blood glucose level or some progressive linear relationship between blood glucose and microvascular changes? Moreover, if the design of the protocol also includes an analysis of the tool used to conduct it, pumps for instance, a third goal is added.
Whatever the goal of this kind of explanatory trial (assuming it is unique and well-defined), the setting up of such an investigation implies certain conditions. In particular, it requires the use of a placebo for a double-blind study. Obviously such a requirement cannot be applied to insulin trials. It is also necessary to test a simple parameter and to study a homogenous selected highly motivated population. Even if it yields highly experimental scientific knowledge of wide application, there will be ethical and practical difficulties because of the design; unless the conventionally treated group is maintained frankly hyperglycaemic for many years, failure to find a difference in the rate of development of microangiopathy would be meaningless.
The use of pumps as tools in an explanatory trial on the effect of blood glucose in diabetic patients is not mandatory since a difference in glycaemic control between groups can be achieved using well established method of conventional insulin therapy [4] . If normoglycaemia is required it has been shown that intensified conventional therapy can achieve this goal [5] . If pumps are used it should be stressed (as was done in the Steno Group report which demonstrated a beneficial effect from producing good glycaemic control) that 'the study (is) not designed as a contest between infusion devices and conventional therapy but a comparison between near normal and moderate levels of glycaemic control' [6] . Such confusions between the goals of a study and the tools used are not always avoided [7] . Moreover, insulin treatment with pumps aimed at achieving perfect control on a very large population of patients may be dangerous: 11 deaths have been reported in patients wearing pumps in the USA in 1981 [8] . These are perhaps due, at least in part, to casual and indiscriminate use in patients not sufficiently trained for 'euglycaemic control treatment' [9] . Finally, a wide utilization of pumps may be difficult since a large number of medical staff is needed and patient compliance in the long term is totally unknown and probably poor.
Whatever the tools to be used for conducting the trial, it seems to us that the cost-benefit ratio of such an explanatory trial -assuming it could be done -will be very poor and will raise the question whether it is really needed.
A final point about this kind of explanatory trial is that any study which mimics a laboratory experiment will not necessarily show what the best treatment is under routine conditions in daily practice for the majority of diabetic patients. Pragmatic clinical trials [3] may help to discover what is the most effective and safe treatment available and/or degree of blood glucose control which is desirable in the long tenn. Perhaps it is wise to accept, occasionally, moderately imperfect control of hyperglycaemia at least at the end of the night instead of running the risk of severe nocturnal hypoglycaemia [10] . Of course 'pragmatic' studies [3] aimed at choosing the most practical treatment for achieving near-normalization of blood glucose levels in diabetic patients who need euglycaemia cannot readily be extrapolated since the treatments studied must be given under routine conditions. Pragmatic trials studying pump treatments are certainly needed. The 'feasibility phase' of the National Institutes of Health trial will thus probably be useful. But, as far as trials on insulin treatment are concerned, we would like to suggest that it would be more rational to spend funds not on explanatory trials but on methods designed to simplify the normalization of glycaemia and to make it safe and available for the majority of diabetic patients.
Yours sincerely G. Tchobroutsky, D. Job, G. Slama and E. Eschwege sated diabetes. In further studies, we documented that in insulin-dependent diabetic patients the increase in potassium following the withdrawal of an insulin infusion, which had maintained the patients euglycaemic overnight, was not correlated with the increase in blood glucose, while it was abolished by somatostatin (which inhibits glucagon) [3] . These data do not exclude the importance of other mechanisms, but suggest again that the increase in glucagon which occurs during non-ketoacidotic decompensation could at least play a part in causing hyperkalaemia. This latter phenomenon could be due to mobilization of potassium from the liver as we have documented in normal subjects [4] .
Yours sincerely, F. Massara, E. Cagliero and G. M. Molinatti
Virus-Induced Diabetes: Cytomegalovirus and Multiple Environmental Insults
Dear Sir, Several viruses can cause diabetes in mice [1] . Encephalomyocarditis (EMC) virus infects pancreatic/3 cells and produces a severe form of diabetes in certain inbred strains of mice [2] . Under some circumstances, reovirus also infects/3 cells, and in addition, triggers an autoimmune response resulting in a mild form of diabetes characterized by abnormalities in glucose tolerance tests which generally disappear within several weeks [3, 4] . Diabetes may also result from cumulative fl cell damage produced by sequential environmental insults. For example, in mice, a sub-diabetogenic dose of streptozotocin reduces the /3 cell reserve and enhances the capacity of certain viruses (e. g., Coxsackie B viruses) to produce diabetes [5, 6] . The present experiments show that murine cytomegalovirus (CMV) infection leads to mild focal fl cell damage, and that multiple environmental insults can increase the severity of diabetes.
Newborn NIH Swiss male and female mice were infected with the Smith strain of CMV [7] or reovirus type 1 that had been passaged more than seven times in mouse pancreatic islet cell cultures to increase their tropism for/3 cells [4] . Two or four weeks later, the mice were challenged with a sub-diabetogenic dose of streptozotocin (1 mg/mouse) [5, 6] , or the D variant of EMC virus [2] , or CMV. Beginning one week after the challenge, each mouse was bled four times, and the glucose index and percentage of animals developing diabetes were determined as described previously [2] . Table 1 shows that when NIH Swiss male mice were infected with only CMV or reovirus, or given only streptozotocin, diabetes did not
